Stock Track | Telix Pharmaceuticals Soars 9.57% Intraday on Strong 2026 Guidance and European Regulatory Progress

Stock Track

Feb 27

Telix Pharmaceuticals Ltd. (TLX) experienced a significant intraday surge of 9.57% on Thursday, reflecting strong investor sentiment toward the company's latest announcements.

The substantial price increase appears to be driven by the company's robust revenue guidance for 2026, projected between US$950 million and US$970 million. This represents a notable increase from its 2025 sales of US$803.79 million, signaling strong growth expectations. Additionally, investors responded positively to Telix's submission of a European marketing authorization application for its glioma imaging candidate, TLX101-Px, which marks an expansion of its oncology imaging portfolio.

The company also filed a shelf registration for its American Depositary Shares, providing potential capital-raising flexibility for future initiatives. While these developments have been well-received by the market, the investment narrative acknowledges ongoing considerations such as pricing pressure in its core PSMA imaging business and general regulatory scrutiny.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1176967494"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176967494\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176967494?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 03:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176967494","market":"sg","top_or_hot":-1,"title":"Stock Track | Telix Pharmaceuticals Soars 9.57% Intraday on Strong 2026 Guidance and European Regulatory Progress","media":"Stock Track","content":"<p>Telix Pharmaceuticals Ltd. (TLX) experienced a significant intraday surge of 9.57% on Thursday, reflecting strong investor sentiment toward the company's latest announcements.</p><p>The substantial price increase appears to be driven by the company's robust revenue guidance for 2026, projected between US$950 million and US$970 million. This represents a notable increase from its 2025 sales of US$803.79 million, signaling strong growth expectations. Additionally, investors responded positively to Telix's submission of a European marketing authorization application for its glioma imaging candidate, TLX101-Px, which marks an expansion of its oncology imaging portfolio.</p><p>The company also filed a shelf registration for its American Depositary Shares, providing potential capital-raising flexibility for future initiatives. While these developments have been well-received by the market, the investment narrative acknowledges ongoing considerations such as pricing pressure in its core PSMA imaging business and general regulatory scrutiny.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Telix Pharmaceuticals Soars 9.57% Intraday on Strong 2026 Guidance and European Regulatory Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Telix Pharmaceuticals Soars 9.57% Intraday on Strong 2026 Guidance and European Regulatory Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 03:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Telix Pharmaceuticals Ltd. (TLX) experienced a significant intraday surge of 9.57% on Thursday, reflecting strong investor sentiment toward the company's latest announcements.</p><p>The substantial price increase appears to be driven by the company's robust revenue guidance for 2026, projected between US$950 million and US$970 million. This represents a notable increase from its 2025 sales of US$803.79 million, signaling strong growth expectations. Additionally, investors responded positively to Telix's submission of a European marketing authorization application for its glioma imaging candidate, TLX101-Px, which marks an expansion of its oncology imaging portfolio.</p><p>The company also filed a shelf registration for its American Depositary Shares, providing potential capital-raising flexibility for future initiatives. While these developments have been well-received by the market, the investment narrative acknowledges ongoing considerations such as pricing pressure in its core PSMA imaging business and general regulatory scrutiny.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX","symbol_name":"Telix Pharmaceuticals Ltd. (Uplisting)","start_time":0,"source_url":"","article_id":"1176967494","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176967494","pubTimestamp":1772133400,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Telix Pharmaceuticals Ltd. (TLX) experienced a significant intraday surge of 9.57% on Thursday, reflecting strong investor sentiment toward the company's latest announcements.The substantial price...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX":"Telix Pharmaceuticals Ltd. (Uplisting)"},"translate_title":"个股赛道|Telix Pharmaceuticals盘中大涨9.57%，因2026年指引强劲及欧洲监管进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX":1},"content_text":"Telix Pharmaceuticals Ltd. (TLX) experienced a significant intraday surge of 9.57% on Thursday, reflecting strong investor sentiment toward the company's latest announcements.The substantial price increase appears to be driven by the company's robust revenue guidance for 2026, projected between US$950 million and US$970 million. This represents a notable increase from its 2025 sales of US$803.79 million, signaling strong growth expectations. Additionally, investors responded positively to Telix's submission of a European marketing authorization application for its glioma imaging candidate, TLX101-Px, which marks an expansion of its oncology imaging portfolio.The company also filed a shelf registration for its American Depositary Shares, providing potential capital-raising flexibility for future initiatives. While these developments have been well-received by the market, the investment narrative acknowledges ongoing considerations such as pricing pressure in its core PSMA imaging business and general regulatory scrutiny.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}